![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/first-patient-enrolled-in-a-phase-2-study-in-patients-with-type-2-diabetes-with-olatecs-nlrp3-inhibitor-dapansutrile-302194959.html
https://www.businesswire.com/news/home/20210428006008/en/Olatec-Therapeutics-Announces-Results-Showing-Dapansutrile-Reduces-Tumor-Growth-in-a-Mouse-Model-of-Melanoma#:~:text=%E2%80%9COur%20studies%20using%20a%20melanoma,growth%20was%20reduced%20in%20mice.